An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Conclude your understanding of lymphoma with an in-depth look at its signs and symptoms, from common indicators to subtle clues.

Speaker : Dr Suvir Singh

Optimizing Treatment Options in Advanced Urothelial Carcinoma

Explore Dr. TamoJit Chaudhury’s expert insights on optimizing advanced urothelial carcinoma treatment, covering immunotherapy, targeted therapy, and clinical trial breakthroughs.

Speakers : Dr. Tamojit Chaudhury

Updates on the First Line Management of ALK+ NSCLC

In this webinar, a detailed discussion is done on Enhancing Outcomes in Advanced Lung Cancer

Speakers : Prof. Tony Mok

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

Join Prof. Jessica Lin as she explores key strategies for managing ALK+ NSCLC while prioritizing long-term patient safety

Speakers : Prof. Jessica Lin

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

Join Prof. Solange Peters as she explores post-progression strategies after first-line third-generation ALK inhibitors in NSCLC.

Speakers : Prof. Solange Peters

Oropharyngeal Cancer in Relation to HPV Status

Learn about the occurrence of oropharyngeal cancer in HPV negative patients through different case presentations.

Speakers : Dr. Ashish M Kaushal

Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Dr. Rohit R Pai compares Nimotuzumab plus chemoradiotherapy vs. placebo plus chemoradiotherapy in locally advanced nasopharyngeal carcinoma (LA-NPC).

Speakers : Dr. Rohit R Pai - Speaker

Role of Nimotuzumab in Management of Nasopharyngeal Cancer

Explore the role of Nimotuzumab in Nasopharyngeal Cancer management with Dr. Abhishek Raj, focusing on targeted therapy and improved patient outcomes.

Speakers : Dr. Abhishek Raj

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

Explore the benefits of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer with Dr. Shailesh Bondarde.

Speakers : Dr Shailesh Bondarde

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

Discover how CDK4/6 inhibitors extend progression-free survival (PFS) and overall survival (OS) in HR+/HER2- metastatic breast cancer (mBC) patients.

Speakers : Dr Parveen Jain

First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials

Explore expert insights on first-line maintenance therapy for metastatic urothelial carcinoma in this panel discussion featuring Dr. Tushar Patil, Dr. Varun Nagori, and Dr. Amol Dongre.

Speakers : Dr Tushar Patil ,Dr Varun Nagori ,Dr Amol Dongre


Recommended News For You

Despite reports of hundreds of cancer cases, carcinogens have been discovered at nuclear missile sites in Montana.

Lentiviral Gene Therapy Shows Promise in Severe Hemophilia A

Prostate cancer mortality is significantly reduced when docetaxel is used.

There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.

Cardiomyocytes are shielded from chemotherapy damage by mitochondrial proteins.

Dual-action mRNA vaccine takes aim at aggressive skin cancer

In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.

Recommended Articles For You

Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study 

The Importance of Understanding Your D-Dimer Levels: A Comprehensive Guide 

Interpreting Iron Studies: What Your Blood Results Really Mean  

All You Need To Know About Melanoma Maligna: Causes, Symptoms & Treatment 
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Advanced Solid Tumors May Benefit from Investigative Immunotherapy Combo.

2.

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

3.

FDA Approves First Menin Inhibitor for Acute Leukemia

4.

Charles III, King of Kings, is Cancerous.

5.

Obesity-related cancers are more likely in people who are obese in both healthy and unhealthy ways.

1.

From Bench to Bedside: The New Era of Lymphoma Treatment and Education

2.

The Unfolding Revolution of Precision Medicine, Immunotherapy, and Digital Transformation in Medical Oncology 2025

3.

What Is Carboxyhemoglobin And How Can It Affect Your Health?

4.

The Pivotal Role of Telomerase in Breast Cancer Therapy Resistance and Treatment Strategies

5.

Understanding Neutropenic Fever: What It Is and Why it's a Serious Concern 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV

2.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III

3.

Current Scenario of Cancer- Palliative Care to Close the Care Gap

4.

Learning About Different Treatment Approaches For Acute Lymphoblastic Leukemia

5.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot